There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
A patient's medical history may not necessarily mean there is a definite treatment risk, and that is where the art of medicine comes in, says Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.
Transcript
What are the key considerations when determining whether a patient with atopic dermatitis (AD) is a suitable candidate for oral Janus kinase (JAK) inhibitors, and how do these considerations differ among various patient demographics such as pediatric versus adult populations, or patients with specific comorbidities?
So, in one sense, when it came to atopic dermatitis therapy for moderate to severe patients, it used to be easy but difficult at the same time. Easy in the sense that we didn't have that many choices; difficult because we didn't have that many choices. So, it was really hard to actually treat folks.
Now, fast forward a number of years, and today we have a handful of options, the newest ones of which are the oral JAK inhibitors. A question that I oftentimes get asked is, "We have choices of biologic therapies and oral JAK inhibitors, when am I thinking about using one or the other?" I let the data and the label and clinical experience guide that decision making process. So, in theory, oral JAK inhibitors are theoretical first-line agents for many of your moderate to severe patients that are 12 [years] and above.
When it comes to thinking about practically speaking the way that those labels are constructed, usually you're going to be thinking about somebody who's had a systemic therapy previously. That could really be anything from a steroidal therapy to a steroid-sparing agent, biologic, what not, and then an oral JAK inhibitor might be what you consider.
Beyond that, there's a few points of the label that are important to think about. The box warning statement is one that is complex and worthy of a very long bit of discussion in its own right. But the bottom line is that if your patient has a very strong history of, or active, cardiovascular issues, malignancy, infectious issue, thromboembolic problem, [then] they're probably not the best candidate. But, I think that this is a bit of a gray area as well, because we understand that medical history doesn't necessarily convey 100% risk for patients. This is where the art of medicine comes in. There is a lot of shared decision making that goes in place when it comes to thinking about what you value, what the patient values, and what the risk-benefit trade off is going to be.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More